To learn whether peripheral 77G7 administration can inhibit AD O‐tau induced tau pathology, we intravenously injected 15 μg 77G7 in 200 μl saline 1 week before the unilateral injection of 0.55 μg AD O‐tau into the hippocampus of 9‐11‐month‐old Tg/hTau mice and followed by weekly iv‐injection of 77G7 for 5 weeks (Figure 6A). This evidence concerns the gene MAPT and Alzheimer disease.